Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

InspireMD (NSPR) EBITDA (2016 - 2025)

InspireMD filings provide 16 years of EBITDA readings, the most recent being $27.3 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 56.64% to $27.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.2 million, a 52.51% decrease, with the full-year FY2025 number at -$10.2 million, down 52.51% from a year prior.
  • EBITDA hit $27.3 million in Q4 2025 for InspireMD, up from -$13.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $27.3 million in Q4 2025 to a low of -$13.1 million in Q3 2025.
  • Median EBITDA over the past 5 years was -$4.8 million (2022), compared with a mean of -$3.6 million.
  • Biggest five-year swings in EBITDA: crashed 83.64% in 2021 and later skyrocketed 400.05% in 2024.
  • InspireMD's EBITDA stood at -$3.9 million in 2021, then decreased by 25.57% to -$4.9 million in 2022, then decreased by 17.67% to -$5.8 million in 2023, then skyrocketed by 400.05% to $17.4 million in 2024, then skyrocketed by 56.64% to $27.3 million in 2025.
  • The last three reported values for EBITDA were $27.3 million (Q4 2025), -$13.1 million (Q3 2025), and -$13.0 million (Q2 2025) per Business Quant data.